enGene Therapeuti…
CACADenGene Therapeutics Inc. (US:ENGN) — Biotechnology: Biological Products (No Diagnostic Substances). Biržų, kuriose prekiaujama bendrovės akcijomis, skaičius: 1. Šiame puslapyje — kaina ir grafikas, dividendai, didžiausi akcininkai ir akcijų skaičiaus istorija.
Apie Įmonę
- Svetainė
- engene.com
- Sektorius
- Health Care · Biotechnology: Biological Products (No Diagnostic Substances)
- Būstinė
- SAINT-LAURENT, Canada
- Generalinis Direktorius
- Ronald H. W. Cooper
- Darbuotojai
- 81
- Apyvartoje Esančios Akcijos
- 67.02 mln. 2026-09-02 duomenimis
- Laisvai Apyvartinės Akcijos
- 32.75 mln.
- Rinkos Kapitalizacija
- 132.02 mln. USD
- Insaideriai
- 0.11%
- Instituciniai Investuotojai
- 84.11%
- Šaka (SIC)
- Biological Products, (No Diagnostic Substances)
- P/E
- nuostolis
- FCF
- −104 mln. USD
- Skola
- 25.2 mln. USDgrynieji pinigai
- Pelnas ir FCF – už 12 mėnesių iki 31.07.2026 (naujausia įmonės ataskaita).
- NAV
Aprašymas
enGene Therapeutics Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company in Canada. The company develops genetic medicines to help patients suffering from bladder cancer. Its lead product candidate is detalimogene voraplasmid, a monotherapy for the treatment of non-muscle invasive bladder cancer (NMIBC). Its pipeline includes LEGEND, which is in Phase 2. The company was formerly known as enGene Holdings Inc. and changed its name to enGene Therapeutics Inc. in April 2026. enGene Therapeutics Inc. is based in Montreal, Canada.
Biržos ir Tikeriai
| Birža | Tikeris | Valiuta | Kaina | Tipas |
|---|---|---|---|---|
| US USA Stocks | ENGN | USD | 1.67 -2.34% | paprastosios akcijos |
Didžiausi Akcininkai
| Turėtojas | Dalis | Akcijos | Ataskaitos Data |
|---|---|---|---|
| FCPM III Services B.V. | 14.37% | 9.63 mln. | 2026-06-30 |
| BML Capital Management,… | 9.95% | 6.67 mln. | 2026-06-30 |
| Siren, L.L.C. | 9.34% | 6.26 mln. | 2026-06-30 |
| Perceptive Advisors Llc | 7.2% | 4.82 mln. | 2026-06-30 |
| Ameriprise Financial, In… | 3.99% | 2.68 mln. | 2026-06-30 |
| Nextech Invest, Ltd. | 3.47% | 2.32 mln. | 2026-06-30 |
| Adar1 Capital Management… | 3.14% | 2.1 mln. | 2026-06-30 |
| Vestal Point Capital, LP | 2.49% | 1.67 mln. | 2026-06-30 |
| Acorn Capital Advisors,… | 1.9% | 1.27 mln. | 2026-06-30 |
| Peapod Lane Capital LLC | 1.64% | 1.1 mln. | 2026-06-30 |
| Franklin Strategic Serie… | 0.73% | 486 579 | 2026-04-30 |
| Fidelity Concord Street… | 0.05% | 34 982 | 2026-07-31 |
| ETFis Series Trust I-Vir… | 0.05% | 32 625 | 2026-04-30 |
| TIFF INVESTMENT PROGRAM-… | 0.02% | 10 639 | 2026-06-30 |
| JNL Series Trust-JNL/DFA… | 0.01% | 9 974 | 2026-06-30 |
| Exchange Place Advisors… | 0.01% | 7 649 | 2026-06-30 |
| GROSSMAN WILLIAM (Office… | ≈0.01% | 5 102 | 2026-09-22 |
| Advanced Series Trust-AS… | 0% | 1 376 | 2026-06-30 |
| FORBION GROWTH OPPORTUNI… | — | — | 2024-10-30 |
